Biogen's Alzheimer’s drug fails to meet mid-stage trial goal
14/05/2026 12:02
May 14 (Reuters) - Biogen BIIB.O said on Thursday its Alzheimer’s drug did not meet the main goal of a mid-stage trial. (Reporting by Kamal Choudhury in Bengaluru; Editing by Jonathan Ananda) ((Kamal.Choudhury@thomsonreuters.com;))
Recent news on Biogen
See all newsUS RESEARCH ROUNDUP-Autodesk, Metlife, Rollins
Brief: Biogen Says DZP Plus Soc Meets Primary Endpoint Of BICLA Response At Week 48
Brief: Biogen Provides Update On Private Payer Coverage For Zurzuvae™ (Zuranolone)
US RESEARCH ROUNDUP-Eli Lilly, General Dynamics, S&P Global
US RESEARCH ROUNDUP-Baker Hughes, Brinker International, GE Vernova